Curaleaf Holdings, Inc. (CURLF) said it responded on October 19, 2026, to Aurora's rejection of Curaleaf's enhanced proposal.
Curaleaf Holdings, Inc. announced on October 6, 2026, that it had issued a press release about an update to the offering circular for Aurora Cannabis Inc. The information, including the press release, is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically referenced.
Curaleaf Holdings, Inc. (symbol: CURLF) is the issuer of record for a Form 8-K filing submitted to the SEC.
Curaleaf Holdings, Inc. (symbol: CURLF) is the issuer of record for a Form 8-K filing submitted to the SEC.
Curaleaf Holdings, Inc. (CURLF) approved compensation arrangements for Chairman and Chief Executive Officer Boris Jordan. His target 2027 short-term incentive opportunity increased from 125% to 200% of his 2027 base salary. Jordan was also awarded a discretionary target bonus of $1 million tied to strategic targets to be evaluated by the Board and Compensation Committee; the award amount is to be determined in March 2028.
Curaleaf granted Jordan 1,344,275 time-based restricted stock units with a grant date fair value of $15,448,435. They will vest in full on January 5, 2028, under the company's 2018 Stock and Incentive Plan.
Curaleaf Holdings, Inc. (CURLF) plans to report financial and operating results for the third quarter ended September 30, 2026, after market close on November 3, 2026. A conference call and audio webcast are scheduled for 5:00 p.m. ET that afternoon.
Curaleaf Holdings, Inc. (CURLF) was added to the FTSE Canada All Cap Index, effective after the close of trading on September 18, 2026. The index measures the performance of large-, mid- and small-capitalization companies listed in Canada.
This is Curaleaf’s second major Canadian benchmark inclusion, following its addition to the S&P/TSX Composite Index under the Health Care sector in September 2025.
Curaleaf Holdings, Inc. (CURLF) is pursuing a tender offer to acquire Aurora and has circulated a detailed brochure to Aurora shareholders encouraging them to tender into Curaleaf’s offer. The consideration per Aurora share is 0.3463 Curaleaf shares plus US$0.75 in cash, implying an offer price of US$4.00.
The brochure highlights that this represents a 45% premium to Aurora’s 30‑day volume weighted average price of US$2.76 as of August 10, 2026, and a 110% premium on an ex‑cash basis. Curaleaf describes the combined business as a global cannabis leader with operations in 17 countries, more than US$1.5 billion of last‑twelve‑month revenue and nearly US$350 million of adjusted EBITDA, plus at least US$40 million of expected annual cost synergies.
The materials contrast Curaleaf’s positive share performance and cash generation with Aurora’s recent declines in revenue and adjusted EBITDA and its use of equity issuance, and state that Aurora shareholders must tender their shares before December 1, 2026 if they wish to participate in the offer.
Curaleaf Holdings, Inc. (CURLF) reports that on September 16, 2026 it published a brochure addressed to shareholders of Aurora, encouraging them to tender their Aurora shares into Curaleaf’s offer.
The brochure is furnished as Exhibit 99.1 to this report and is being treated as furnished, not filed, for Exchange Act liability purposes.